While various immunotherapies work through different mechanisms, they are all designed to enhance the immune system’s ability to recognize and target cancer cells. Pembrolizumab does so by binding and inhibiting PD-1, a protein that normally protects the body from attacking itself.
The newly released 2021 WHO Classification of Tumors of the Central Nervous System (CNS) introduces major changes that advance the role of molecular profiling in CNS tumor classification and includes ma
Previous immunotherapies like CAR T cells were designed to target glioblastoma cells, but were only effective in killing a portion of the cells – leaving some cancer cells behind, and allowing for tumor recurrence.
The UCSF Brain Tumor Center is leading a new randomized, double-blind, placebo-controlled, phase 3 clinical trial of enzastaurin combined with temozolomide and radiatio
Researchers at UC San Francisco have discovered how PGAM1 – a protein expressed at high levels in many cancers – can contribute to tumor cells’ resistance to radiation therapy and chemotherapy.